Patents by Inventor Aniela Jakubowski
Aniela Jakubowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150291688Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: ApplicationFiled: March 18, 2015Publication date: October 15, 2015Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Patent number: 9011859Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: GrantFiled: April 11, 2013Date of Patent: April 21, 2015Assignee: Biogen Idec MA Inc.Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Publication number: 20130216496Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: ApplicationFiled: April 11, 2013Publication date: August 22, 2013Applicant: BIOGEN IDEC MA INC.Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Patent number: 8506958Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: GrantFiled: April 3, 2009Date of Patent: August 13, 2013Assignee: Biogen IDEC MA Inc.Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Publication number: 20120015024Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: ApplicationFiled: July 8, 2011Publication date: January 19, 2012Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Publication number: 20110002924Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: ApplicationFiled: April 7, 2010Publication date: January 6, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Patent number: 7731963Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: GrantFiled: March 20, 2007Date of Patent: June 8, 2010Assignee: Biogen Idec MA Inc.Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Publication number: 20090311313Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: ApplicationFiled: April 3, 2009Publication date: December 17, 2009Inventors: LINDA C. BURKLY, ANIELA JAKUBOWSKI, TIMOTHY ZHENG, KYUNGMIN HAHM
-
Publication number: 20080008714Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: ApplicationFiled: March 20, 2007Publication date: January 10, 2008Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Patent number: 7208151Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: GrantFiled: September 12, 2001Date of Patent: April 24, 2007Assignee: Biogen Idec MA Inc.Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Publication number: 20060240004Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.Type: ApplicationFiled: April 9, 2003Publication date: October 26, 2006Inventors: Linda Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
-
Publication number: 20060003932Abstract: The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.Type: ApplicationFiled: June 2, 2005Publication date: January 5, 2006Inventors: Aniela Jakubowski, Linda Burkly
-
Patent number: 6943146Abstract: The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.Type: GrantFiled: May 7, 2001Date of Patent: September 13, 2005Assignee: Biogen Idec MA Inc.Inventors: Aniela Jakubowski, Linda Burkly
-
Publication number: 20040033225Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.Type: ApplicationFiled: March 14, 2003Publication date: February 19, 2004Inventors: Jeffrey Browning, Linda Burkly, Aniela Jakubowski, Timothy Zheng
-
Publication number: 20030211993Abstract: The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.Type: ApplicationFiled: November 8, 2002Publication date: November 13, 2003Inventors: Aniela Jakubowski, Linda Burkly